High alert medication
ACP with endorsement and training
Coronary reperfusion in ST elevation myocardial infarction
Patient must meet criteria for entry into CHAMP pathway
Follow weight and age-based dosing
For intravenous administration only. Push over 5 seconds.
Not authorized in pediatrics
Tenecteplase is a modified form of human tissue plasminogen activator (tPA) binding to fibrin and converting plasminogen to plasmin.
Following a single bolus dose of tenecteplase:
The most frequent adverse reaction associated with tenecteplase is bleeding.
Overdose is considered unlikely.